ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

27 8 2025 13:05:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

18 8 2025 13:05:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

12 8 2025 13:05:01 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 8 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 7 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 6 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

28 5 2025 13:05:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

28 5 2025 13:05:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

27 5 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

27 5 2025 05:00:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

05 5 2025 13:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 5 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

28 4 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 4 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

31 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

25 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

25 2 2025 13:15:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

18 2 2025 13:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 2 2025 13:30:00 提供 Nasdaq GlobeNewswire